Assessing Value of CRP/Alb and Pan-immune-inflammation Value in the Prognosis of PD-1/PD-L1 Inhibitors in the Treatment of Pa-tients with Advanced Non-small Cell Lung Cancer
10.11969/j.issn.1673-548X.2023.12.033
- VernacularTitle:CRP/Alb、泛免疫炎症值对PD-1/PD-L1抑制剂治疗晚期非小细胞肺癌患者预后的评估价值
- Author:
Aihong LV
1
;
Hongbing WANG
;
Fang XU
Author Information
1. 221000 徐州医科大学研究生学院
- Keywords:
CRP/Alb;
Pan-immune-inflammatory value;
Prognosis;
Non-small cell lung cancer
- From:
Journal of Medical Research
2023;52(12):166-171
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the assessing value of C-reactive protein to serum albumin ratio(CRP/Alb)and pan-im-mune-inflammation value(PIV)in the prognosis of advanced non-small cell lung cancer(NSCLC)before receiving first-line PD-1/PD-L1 inhibitors combined with chemotherapy.Methods The clinical data of 85 patients diagnosed with advanced NSCLC in the Affili-ated Hospital of Xuzhou Medical University from November 2018 to December 2021 who received first-line treatment with PD-1/PD-L1 inhibitors combined with chemotherapy regimens were retrospectively analyzed.The receiver operator characteristic curve(ROC curve)was used to determine the optimal cut-off value of CRP/Alb and PIV,and univariate and multivariate analysis were performed on the COX proportional risk regression model.Results In this study,a total of 85 patients were included,and the optimal cut-off value of CRP/Alb was 0.38,and the difference between the advanced NSCLC patients in the high and low CRP/Alb groups in the history of smok-ing and hypertension was statistically significant(P＜0.05);the optimal cut-off value of PIV was 666.77,and the difference in ECOG-PS scores between the advanced NSCLC patients in the high and low PIV groups was statistically significant(P＜0.05).The dis-ease control rate(DCR)and progression-free survival(PFS)of patients in the high CRP/Alb group and the high PIV group were lower than those in low CRP/Alb and low PIV groups,and the difference was statistically significant(P＜0.05).Univariate and multivariate COX regression analysis showed that high CRP/Alb and high PIV were predictors of poor prognosis of PFS in patients with advanced NSCLC in the first-line treatment of PD-1/PD-L1 inhibitors and chemotherapy regimens.Conclusion High CRP/Alb and high PIV are associated with poorer PFS in patients with advanced NSCLC,and may be potentially valuable prognostic factors for patients with ad-vanced NSCLC treated with first-line immunotherapy combined with chemotherapy.
